Plasma Clearance of Lovastatin Versus Chinese Red Yeast Rice in Healthy Volunteers
Authors:
- 1 December 2005
- journal article
- research article
- Published by SAGE Publications in The Journal of Alternative and Complementary Medicine
- Vol. 11 (6) , 1031-1038
Abstract
Objectives: It is now accepted that inhibition of cholesterol biosynthesis is effective in the primary and secondary prevention of heart disease. However, the perceived side-effects on muscle and liver reduce the general acceptance of statin drug therapy as well as compliance over the long term, which is necessary for prevention efforts to be successful. Chinese red yeast rice (CRYR) is a supplement containing lovastatin (monacolin K), eight other monacolins, pigments, tannins, and other phytochemicals. The authors previously reported on a double- blind placebo-controlled trial of CRYR supplement in 80 individuals demonstrating a significant decrease in cholesterol levels from 250 mg/dL to 210 mg/dL over 8 weeks independent of diet. The current study compared the pharmacokinetics of CRYR with lovastatin at the same bioeffective dose for lowering cholesterol. Methods: Eleven (11) healthy volunteers were randomized to a crossover study taking 2400 mg CRYR or 20 mg of lovastatin. Results: The Cmax and area under the curve (AUC) of lovastatin were 22.42 ng/mL, and 80.47 higher than CRYR (p = 0.001 and 0.002, respectively). The Cmax for lovastatin hydroxy-acid was 36.63 ng/mL higher than the Cmax of CRYR hydroxy-acid (p = 0.001). The AUC of lovastatin hydroxy-acid was 258.5 greater than that of CRYR (p = 0.001). Conclusions: The results suggested that the effect of CRYR on the cholesterol concentration might be caused by the additive and/or synergistic effects of monacolin K with other monacolins and substances in CRYR. It may lead to the ultimate development of a botanical supplement based on CRYR.Keywords
This publication has 22 references indexed in Scilit:
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesJACC, 2004
- Safety of StatinsCirculation, 2004
- Analytical methods for the quantitative determination of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in biological samplesJournal of Chromatography B, 2003
- Inhibitory Effect of Red Koji Extracts on Mushroom TyrosinaseJournal of Agricultural and Food Chemistry, 2003
- Pharmacokinetics of lovastatin extended‐release dosage form (Lovastatin XL) in healthy volunteersBiopharmaceutics & Drug Disposition, 2002
- An Analysis of Nine Proprietary Chinese Red Yeast Rice Dietary Supplements: Implications of Variability in Chemical Profile and ContentsThe Journal of Alternative and Complementary Medicine, 2001
- Surveys of Complementary and Alternative Medicine: Part I. General Trends and Demographic GroupsThe Journal of Alternative and Complementary Medicine, 2001
- Biological activities of oligoketide pigments of Monascus purpureusFood Additives & Contaminants, 1999
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Inhalation of levomepromazine in severe acute asthmaThe Lancet, 1994